Optimer Rides High After OPT-80 C. Difficile Trial Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Optimer Pharmaceuticals saw its share price double from around $4 to $8 after it released data from a Phase III trial showing its orally dosed first-in-class macrocyclic antibiotic was at least as good as Vancocin (ViroPharma's oral vancomycin) - and possibly better - at treating the hospital scourge Clostridium difficile.